4DMT’s CF gene therapy posts early cues for improving patient outcomes
Pharmaceutical Technology
JUNE 8, 2023
It is administered through inhalation and is initially developed for use in patients who do not respond to CFTR modulators. Topic sponsors are not involved in the creation of editorial content. Mutations in CFTR result in cystic fibrosis, an inherited disorder where patients’ lungs and other organs are damaged by mucus build-up.
Let's personalize your content